465 Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC)
Publication
, Conference
Kapoun, A; O'Reilly, E; Cohn, A; Bendell, JC; Smith, L; Strickler, JH; Gluck, W; Liu, YW; Wallace, B; Tam, R; Cancilla, B; Brunner, A ...
Published in: European Journal of Cancer
November 2014
Duke Scholars
Published In
European Journal of Cancer
DOI
ISSN
0959-8049
Publication Date
November 2014
Volume
50
Start / End Page
152 / 152
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Kapoun, A., O’Reilly, E., Cohn, A., Bendell, J. C., Smith, L., Strickler, J. H., … Wang, M. (2014). 465 Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC). In European Journal of Cancer (Vol. 50, pp. 152–152). Elsevier BV. https://doi.org/10.1016/s0959-8049(14)70591-x
Kapoun, A., E. O’Reilly, A. Cohn, J. C. Bendell, L. Smith, J. H. Strickler, W. Gluck, et al. “465 Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC).” In European Journal of Cancer, 50:152–152. Elsevier BV, 2014. https://doi.org/10.1016/s0959-8049(14)70591-x.
Kapoun A, O’Reilly E, Cohn A, Bendell JC, Smith L, Strickler JH, et al. 465 Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC). In: European Journal of Cancer. Elsevier BV; 2014. p. 152–152.
Kapoun, A., et al. “465 Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC).” European Journal of Cancer, vol. 50, Elsevier BV, 2014, pp. 152–152. Crossref, doi:10.1016/s0959-8049(14)70591-x.
Kapoun A, O’Reilly E, Cohn A, Bendell JC, Smith L, Strickler JH, Gluck W, Liu YW, Wallace B, Tam R, Cancilla B, Brunner A, Hill D, Zhou L, Dupont J, Zhang C, Wang M. 465 Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC). European Journal of Cancer. Elsevier BV; 2014. p. 152–152.
Published In
European Journal of Cancer
DOI
ISSN
0959-8049
Publication Date
November 2014
Volume
50
Start / End Page
152 / 152
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis